The human immunodeficiency virus uses the human complement system to its advantage. Is it possible to turn the tables with a vaccine?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A novel trifunctional IgG-like bispecific antibody to inhibit HIV-1 infection and enhance lysis of HIV by targeting activation of complement
Virology Journal Open Access 29 June 2010
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Atkinson, J.P., Odlesby, T.J., White, D.J.G., Adams, E.A. & Liszewski, M.K. Separation of self from non-self in the complement system. A role for membrane cofactor protein and decay accelerating factor. Clin. Exp. Immun. 86, 27–30 (1991).
Bach, F.H. et al. Barriers to xenotransplantation. Nature Med. 1, 869–873 (1995).
Cozzi, E. & White, D.J.G. The generation of transgenic pigs as potential organ donors for humans. Nature Med. 1, 964–966 (1995).
Dierich, M.P. et al. HIV and human complement: Mechanisms of interaction and biological implications. Immunol. Today 14, 435–440 (1993).
Stoiber, H., Pinter, C., Siccardi, A.G., Clivio, A. & Dierich, M.P. Efficient destruction of HIV in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J. Exp. Med. (in the press).
Marschang, P., Sodroski, J., Würzner, R. & Dierich, M.P. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur. J. Immunol. 25, 285–290 (1995).
Saifuddin, M. et al. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell-line derived and primary isolates of HIV 1. J. Exp. Med. 182, 501–509 (1995).
Gelderblom, H.R. Assembly and morphology of HIV: Potential effect of structure on viral function. AIDS 5, 617–637 (1991).
Arthur, L.O. et al. Cellular proteins bound to immunodeficiency viruses: implication for pathogenesis and vaccines. Science 258, 1935–1938 (1992).
Orentas, R.J. & Hildreth, J.E.K. Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV. AIDS Res. Hum. Retrovir. 9, 1157–1165 (1993).
Morgan, B.P. & Meri, S. Membrane proteins that protect against complement lysis. Immuno-pathology 15, 369–396 (1994).
Ebenbichler, C., Thielens, N., Arlaud, G. & Dierich, M.P. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J. Exp. Med. 174, 944–952 (1991).
Stoiber, H., Thielens, N., Ebenbichler, C., Arlaud, G. & Dierich, M.P. The envelope glycoprotein of HIV-1 gp120 and the human complement protein Clq bind to the same peptides derived from three different regions of gp41, the transmembrane glycoprotein of HIV-1, and share antigenetic homology. Eur. J. Immunol. 24, 294–300 (1994).
Sölder, B.M. et al. Complement receptors: Another port of entry for HIV. Lancet ii, 271–272 (1989).
Reisinger, E. et al. Complement-mediated enhancement of HIV-1 infection of the monoblastoid cell line U937. AIDS 4, 961–965 (1989).
Tremblay, M.S., Meloche, S., Sekaly, R.P. & Wainberg, M.A.J. Complement receptor 2 mediates enhancement of human immunodeficiency virus 1 infection in Epstein-Barr virus carrying B cells. Exp. Med. 171, 1791–1796 (1990).
Boyer, V., Desgranges, C., Trabaud, M.A., Fischer, E. & Kazatchkine, M.D. Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4-and antibody-independent fashion. J. Exp. Med. 173, 1151–1158 (1991).
Robinson, E.W., Montefiori, D.C. & Mitchell, W.M. Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. Virology 175, 600–604 (1990).
Joling, P. et al. Binding of human immunodeficiency virus type 1 to follicular dendritic cells in vitro is complement dependent. J. Immunol. 150, 1065–1073 (1993).
Pintér, C., Siccardi, A.G., Longhi, R. & Clivio, A. Direct interaction of complement factor H with the C1 domain of HIV-1 gp120. AIDS Res. Hum. Retrovir. 11, 577–588 (1995).
Stoiber, H., Ebenbichler, C., Schneider, R., Janatova, J. & Dierich, M.P. Interaction of several complement proteins with gp120 and gp41, the two envelope glycoproteins of HIV-1. AIDS 9, 19–26 (1995).
Pintér, C., Siccardi, A.G., Lopalco, L., Longhi, R. & Clivio, A. HIV gp41 and complement factor H interact with each other and share functional as well as antigenic homology. AIDS Res. Hum. Retrovir. 11, 971–980 (1995).
Stoiber, H., Schneider, R., Janatova, J. & Dierich, M.P. Human complement proteins C3b, C4b, factor H and properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1. Immunobiology 193, 98–113 (1995).
Morgan, B.P. & Walport, M.J. Complement deficiency and diseases. Immunol. Today 12, 301–306 (1991).
Kinoshita, T. Biology of complement: The overture. Immunol. Today 12, 291–295 (1991).
Bhakdi, S. & Tranum-Jensen, J. Complement lysis: A hole is a hole. Immunol. Today 12, 318–320 (1991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dierich, M., Stoiber, H. & Clivio, A. A “complement–ary” AIDS vaccine. Nat Med 2, 153–155 (1996). https://doi.org/10.1038/nm0296-153
Issue Date:
DOI: https://doi.org/10.1038/nm0296-153
This article is cited by
-
Complement and HIV-I infection/HIV-associated neurocognitive disorders
Journal of NeuroVirology (2014)
-
A novel trifunctional IgG-like bispecific antibody to inhibit HIV-1 infection and enhance lysis of HIV by targeting activation of complement
Virology Journal (2010)
-
The good and evil of complement activation in HIV-1 infection
Cellular & Molecular Immunology (2010)